SCHEMBL3943247

SCHEMBL3943247

C=CCCCC[C@H](CNOc1ccccc1)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TBXAS1 P24557 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 2/20 0.36
GLA P06280 1/20 0.36
HTT P42858 1/20 0.36
RAB9A P51151 1/20 0.36
FOLH1 Q04609 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2C19 P33261 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
CASP1 P29466 1/20 0.34
METAP2 P50579 2/20 0.33
METAP1 P53582 2/20 0.33
OPRD1 P41143 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3943243 0.82 FOLH1 (0.39) ALDH1A1TBXAS1RAB9AFOLH1KDM4E
SCHEMBL4405484 0.78 FOLH1 (0.40) ALDH1A1TBXAS1RAB9AFOLH1KDM4E
SCHEMBL4405482 0.78 FOLH1 (0.40) ALDH1A1TBXAS1RAB9AFOLH1KDM4E
SCHEMBL3944732 0.78 METAP2 (0.43) ALDH1A1L3MBTL1SMN1; SMN2GAAGLA
SCHEMBL23833831 0.75 FOLH1 (0.62) TBXAS1FOLH1
SCHEMBL3944750 0.73 TBXAS1 (0.35) ALDH1A1L3MBTL1TBXAS1SMN1; SMN2HTT
SCHEMBL4016679 0.73 MAPT (0.50) ALDH1A1SMN1; SMN2FOLH1TDP1
SCHEMBL3804921 0.71 MAPT (0.54) ALDH1A1SMN1; SMN2FOLH1TDP1
SCHEMBL21439803 0.71 MAPT (0.54) ALDH1A1SMN1; SMN2FOLH1TDP1
SCHEMBL4015850 0.71 MAPT (0.54) ALDH1A1SMN1; SMN2FOLH1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7507726-B2 Peptide deformylase inhibitors SMITHKLINEBEECHAM CORPORATION (US) 2009-03-24 US disclosed
EP-1654239-A4 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2008-10-01 EP disclosed
US-20080167302-A1 Peptide Deformylase Inhibitors GLAXOSMITHKLINE LLC 2008-07-10 US disclosed
EP-1654239-A2 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP disclosed
WO-2005017124-A2 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167302-A1 Peptide Deformylase Inhibitors PDF, PEPD, DPEP1 ALDH1A1 4302/4885L3MBTL1 1474/4885TBXAS1 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.